Announcements Trials
Browse Landscape

Status

No longer available 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 70Observational 9Expanded_access 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 3Skin Neoplasms 1Progressive Metastatic Castrate Resistant Prostate Cancer 1

Interventions

trametinib 3dabrafenib 3talimogene laherparepvec 2pembrolizumab 2Nivolumab 2Ipilimumab 2ulixertinib 1tebentafusp 1pegilodecakin 1omaveloxolone 1lifileucel 1efineptakin alfa 1balstilimab 1aldesleukin 1Melphalan 1Cyclophosphamide 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Expanded_access × Melanoma × trametinib × Clear all
NCT04489433 2025-12-18

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Novartis

No longer available
Dermatologic

Melanoma

NCT04544202 2024-11-12

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

Novartis

No longer available
Dermatologic

Melanoma, Skin Neoplasms

NCT02416232 2017-08-15

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

GlaxoSmithKline

No longer available
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡